Drug-resistant epilepsy is characterized by the persistence of seizures despite the use of at least two appropriate antiseizure medications at effective doses.
Despite the availability of over 20 ASMs, achieving seizure control in DRE patients remains difficult.
Transforming Epilepsy Treatment
Pioneering Solutions for Drug-Resistant Epilepsy
Epilepsy affects over 70 million people worldwide, and approximately one-third of these individuals suffer from drug-resistant epilepsy (DRE), where seizures persist despite treatment with multiple antiseizure drugs. Our mission is to address this significant unmet need by developing innovative therapies that target the root causes of epilepsy.
Our Breakthrough Approach
Harnessing the Power of 5-HT2C Agonists
Our lead candidate BMB-101,a novel 5-HT2C agonist, represents a new frontier in epilepsy treatment. By targeting specific serotonin receptors, we aim to reduce seizure frequency and improve the quality of life for patients with drug-resistant epilepsy.
Why It Matters
Addressing the Urgent Need for Effective Therapies
Drug-resistant epilepsy not only increases the risk of premature death and injuries but also significantly impacts the psychosocial well-being and quality of life of those affected. Our research is dedicated to overcoming these challenges and providing hope to patients and their families.
Join Us on Our Journey
Innovating for a Seizure-Free Future
We are committed to transforming the landscape of epilepsy treatment through rigorous research and development. Our team is driven by the potential to make a meaningful difference in the lives of those living with epilepsy.
×
"*" indicates required fields